Mereo BioPharma(MREO)
UK - LondonPharmaceutical
Focus: Mereo BioPharma is a UK-based public biotech company specializing in the acquisition and rapid development of drugs across oncology, endocrinology, women's health, respiratory, and nephrology. Founded in 2015 and trading on NASDAQ (MREO), it operates a diversified pipeline of early-stage assets.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Mereo BioPharma
AI assessmentNot HiringNo open roles listed right now. Follow Mereo BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Mereo BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$0K
FY2025
Pipeline & Clinical Trials
OMP-305B83
Advanced Solid Tumor MalignanciesClinical Trials (1)
NCT02298387A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
Phase 1Help build intelligence for Mereo BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.